((自动化翻译由路透提供,请见免责声明 ))
1月2日 - ** 药物开发商Neumora Therapeutics 股价下跌82%,至1.95美元
** NMRA称其抑郁症实验药物navacaprant在一项后期试验中没有达到 (link)。
** 该药物没有减轻抑郁症状,根据疾病严重程度量表测量,该量表可追踪悲伤、睡眠减少和悲观的想法
** NMRA称,该药物在一个关键的次要目标上也没有显示出统计学意义上的显著改善
** 该公司称,截至第三季度末,其现金余额为 3.42 亿美元,将为 2026 年中期的运营提供资金支持
** 2024 年的 NMRA 下降了约 38
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.